SG Americas Securities LLC lowered its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 31.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,244 shares of the life sciences company’s stock after selling 6,425 shares during the quarter. SG Americas Securities LLC’s holdings in Integra Lifesciences were worth $682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Whittier Trust Co. acquired a new stake in Integra Lifesciences in the third quarter worth about $169,000. Zions Bancorporation acquired a new stake in Integra Lifesciences in the third quarter worth about $205,000. Quantitative Systematic Strategies LLC acquired a new stake in Integra Lifesciences in the third quarter worth about $264,000. Ameritas Investment Partners Inc. boosted its holdings in Integra Lifesciences by 3.6% in the second quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock worth $295,000 after acquiring an additional 187 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Integra Lifesciences by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 1,466 shares in the last quarter. 90.27% of the stock is currently owned by institutional investors.
IART has been the subject of a number of research reports. TheStreet raised Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Oppenheimer set a $58.00 target price on Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and set a $63.00 target price on shares of Integra Lifesciences in a report on Thursday, March 1st. Barclays reaffirmed a “hold” rating and set a $53.00 target price on shares of Integra Lifesciences in a report on Tuesday, January 9th. Finally, Zacks Investment Research raised Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $54.18.
In related news, Director Keith Bradley sold 15,658 shares of Integra Lifesciences stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $55.00, for a total transaction of $861,190.00. Following the completion of the transaction, the director now directly owns 37,074 shares in the company, valued at $2,039,070. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 21.50% of the stock is currently owned by company insiders.
Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at $53.17 on Wednesday. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85. The firm has a market capitalization of $4,166.48, a P/E ratio of 64.84, a P/E/G ratio of 1.64 and a beta of 0.65. Integra Lifesciences Holdings Corp has a 12-month low of $40.51 and a 12-month high of $56.42.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.08. The company had revenue of $368.60 million during the quarter, compared to analysts’ expectations of $362.64 million. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. Integra Lifesciences’s quarterly revenue was up 44.2% on a year-over-year basis. During the same period last year, the business earned $0.52 earnings per share. equities analysts predict that Integra Lifesciences Holdings Corp will post 2.33 EPS for the current year.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.